erythromycin has been researched along with mci 9038 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Benincosa, LJ; Di Cicco, RA; Hursting, MJ; Jorkasky, DK; Peng, L; Sheth, SB; Tran, JQ; Tucci, M | 1 |
1 review(s) available for erythromycin and mci 9038
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for erythromycin and mci 9038
| Article | Year |
|---|---|
Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban.
Topics: Adolescent; Adult; Analysis of Variance; Anti-Bacterial Agents; Antithrombins; Area Under Curve; Arginine; Cross-Over Studies; Drug Interactions; Erythromycin; Half-Life; Humans; Male; Middle Aged; Pipecolic Acids; Sulfonamides | 1999 |
1 other study(ies) available for erythromycin and mci 9038
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |